Generic Name: brigatinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Takeda

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Alunbrig is an anaplastic lymphoma kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer.

General Info

Alunbrig interferes with anaplastic lymphoma kinase (ALK), ROS1 and other receptor tyrosine kinases that play a role in cancer cell growth.

The ALTA study showed that Alunbrig demonstrated a response rate of about 50% in people with metastatic NSCLC who experienced disease progression on Xalkori (crizotinib). ALTA 1L showed a response rate of 74% for people randomized to receive Alunbrig as their first ALK inhibitor, compared with 62% for those started on Xalkori. Alunbrig was first approved in 2017.


Dosing Info: Alunbrig is taken as a once-daily tablet. If the 90 mg starting dose is well tolerated, the dose can be doubled.

Side Effects

Common adverse reactions include diarrhea, nausea, fatigue, rash, headache, cough shortness of breath and muscle pain. More serious side effects may include lung inflammation, severe high blood pressure, heart rhythm abnormalities, vision problems and severe lab abnormalities. Alunbrig can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: May 23, 2020